Sign in
CompletedPhase 2

Safety and Feasibility of Metformin for Sepsis Induced AKI

Key facts

Who runs it
Hernando Gomez
Where
Pittsburgh, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
80 people enrolled
Started
8 Nov 2023
Ended
18 May 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Metformin low dose
  • Metformin high dose
  • Placebo
Record updated
9 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age > 18 years
  • Admitted to the ICU with sepsis per sepsis 3 criteria (defined as suspected infection or initiation of anti-biotics plus an increase in SOFA ≥ 2 points)
  • Available enteral access

Who cannot take part

  • Metformin use in the last 30 days from admission (assessed by medical or refill prescription history, and by medication reconciliation)
  • History of allergy to metformin
  • Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 prior to study drug administration
  • Having severe metabolic acidosis defined by a venous or arterial pH < 7.2, with PaCO2 < 45 or PvCO2 < 50 mmHg at the time of enrolment; Patients co-enrolled in observational studies will be eligible for enrollment in LiMiT AKI. However, patients enrolled in interventional studies will need to be assessed on an individual basis to define whether the patient will be eligible; Children will be excluded from recruitment for this study. Etiologic causes of sepsis, acute kidney injury, and prognostic factors for children differ from those for adults; and for these reasons the proposed study focuses only on the adult population (age 18 years or older)
  • Not expected to survive more than 24 hours
  • Advanced directive to withhold life-sustaining treatment
  • The treating clinician believes that participation in the trial would not be in the best interests of the patient
  • Known or suspected pregnancy
  • On mechanical circulatory support of any kind

Where in United States

  • University of PittsburghPittsburgh, United States

About the trial

What the trial wants to find out

Acute kidney injury (AKI) is an independent risk factor for death that affects 10-15% of hospitalized patients and more than 50% of patients admitted to the intensive care unit. Sepsis is the most frequent cause of AKI, affecting 48 million people worldwide every year, and accounting for approximately 11 million of annual global deaths. Despite these figures, there are no known therapies to prevent or reverse septic AKI; hence this study aims to establish the safety and feasibility of the implementation of metformin in the treatment of AKI in patients with sepsis.

Read full original descriptionShow less

This study is the first critical step to inform the design of a future, full-scale efficacy randomized clinical trial.

The 3 groups in the trial

  • Metformin 500 mgTreatment being tested

    One 500mg tablet will be administered twice a day for the first (5) days of study treatment.

    Treatment: Metformin low dose

  • PlaceboPlacebo, for comparison

    One inactive tablet will be administered twice a day for the first (5) days of study treatment.

  • Metformin 1,000 mgTreatment being tested

    One 1,000mg tablet will be administered twice a day for the first (5) days of study treatment.

    Treatment: Metformin high dose

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Clinical Trial of the Safety and Feasibility of Metformin as a Treatment for Sepsis Induced AKI.
Publications
Record updated
9 June 2026